Debbie Rigby takes a look at the latest in research news
In addition to effective glycemic control and weight loss, SGLT-2 inhibitor treatment of T2D prevents adverse cardiovascular and renal outcomes in individuals with and without these comorbidities. Reduced rate of hospitalization due to heart failure and improved renal outcomes appear to be class effects of SGLT-2 inhibitors. Reduction in CV events may be more significant in individuals with established cardiovascular disease.
Current Medical Research and Opinion 2020;35:1283-95.
Case reports of ADR to glucosamine and chondroitin sent to the Therapeutic Goods Administration between 2000 and 2011 demonstrate the incidence of hypersensitivity reactions to glucosamine and chondroitin products. Nearly three-quarters of the 366 reported ADRs were found to be hypersensitivity reactions. The results of this investigation support the need for clear labelling on glucosamine and chondroitin preparations to raise awareness of possible adverse events for those predisposed to allergy or atopy in response to shellfish.
Postgraduate Medical Journal 2020.
A meta-analysis of randomised controlled trials shows glucagon-like peptide-1 receptor agonists significantly reduce major adverse cardiovascular events, cardiovascular and total mortality stroke, and hospitalization for heart failure, with a trend for reduction of myocardial infarction, in patients with Type 2 diabetes, with and without established CVD.
European Heart Journal 2020.
A large multicentre trial in the UK found no evidence that daily emollient during the first year of life prevents eczema in high-risk children and some evidence to suggest an increased risk of skin infections. The authors concluded that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn.
Lancet, published February19, 2020.